Mirum Pharmaceuticals Inc (MIRM)
46.26
+2.34
(+5.33%)
USD |
NASDAQ |
Nov 14, 16:00
48.11
+1.85
(+4.00%)
After-Hours: 07:07
Mirum Pharmaceuticals Cash from Financing (Quarterly): 7.291M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 7.291M |
| March 31, 2024 | 1.205M |
| December 31, 2023 | 1.777M |
| September 30, 2023 | 207.13M |
| June 30, 2023 | 114.71M |
| March 31, 2023 | 12.99M |
| December 31, 2022 | -0.329M |
| September 30, 2022 | 86.07M |
| June 30, 2022 | 5.246M |
| March 31, 2022 | 18.10M |
| December 31, 2021 | 0.615M |
| Date | Value |
|---|---|
| September 30, 2021 | 0.345M |
| June 30, 2021 | 65.91M |
| March 31, 2021 | 6.594M |
| December 31, 2020 | 134.51M |
| September 30, 2020 | 2.096M |
| June 30, 2020 | 0.025M |
| March 31, 2020 | 44.66M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 68.42M |
| June 30, 2019 | 58.76M |
| March 31, 2019 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.329M
Minimum
Dec 2022
207.13M
Maximum
Sep 2023
37.31M
Average
6.594M
Median
Mar 2021
Cash from Financing (Quarterly) Benchmarks
| Arcutis Biotherapeutics Inc | 0.394M |
| Cytokinetics Inc | 3.425M |
| Amicus Therapeutics Inc | 18.19M |
| MannKind Corp | -2.342M |
| TG Therapeutics Inc | 134.45M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.803M |
| Cash from Investing (Quarterly) | -72.72M |
| Free Cash Flow | -39.22M |
| Free Cash Flow Per Share (Quarterly) | -0.3087 |
| Free Cash Flow to Equity (Quarterly) | -14.99M |
| Free Cash Flow to Firm (Quarterly) | -14.50M |
| Free Cash Flow Yield | -1.86% |